CANCERLINQ LLC – Trademark Portfolio

Entity Type: 16

CANCERLINQ LLC holds 5 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 5 filings in this category. The portfolio also extends into Class 44 (Medical Services) across 2 Nice Classification classes. Currently, 4 trademarks are registered and 1 is pending. Notable registered marks include TRIALLINQ, CANCERLINQ, and CANCERLINQ DISCOVERY. The owner is based in CAMBRIDGE, MA.

1120 MASSACHUSETTS AVENUE

CAMBRIDGE, MA 02138

5 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

CANCERLINQ LLC's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

42
Computer & Scientific (5 filings)

Scientific and technological services; industrial analysis and research services

44
Medical Services (2 filings)

Medical services; veterinary services; hygienic and beauty care for human beings or animals

Frequently Asked Questions

How many trademarks does CANCERLINQ LLC have?

CANCERLINQ LLC has 5 U.S. trademarks filed with the USPTO. Of these, 4 registered, 1 pending.

What trademark classes does CANCERLINQ LLC file in?

CANCERLINQ LLC files trademarks across 2 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 44 (Medical Services). Class 42 covers scientific and technological services; industrial analysis and research services.

What are CANCERLINQ LLC's most well-known trademarks?

CANCERLINQ LLC's registered trademark portfolio includes well-known marks such as TRIALLINQ, CANCERLINQ, and CANCERLINQ DISCOVERY. These are among 4 currently registered trademarks in the portfolio.

What is CANCERLINQ LLC's trademark registration success rate?

CANCERLINQ LLC has a 100% trademark registration rate, with 4 out of 4 resolved applications resulting in successful registration. Currently, 1 application is pending review.